MENU

May 2022

Conagen’s New Dihydro Resveratrol Made By Clean Bioconversion Inspires Novel Products and Drives Market Growth

Bedford, Mass., May 31, 2022 (GLOBE NEWSWIRE) — Massachusetts-based biotech Conagen announces the development of a new scalable natural compound, dihydro resveratrol, for use in industrial and human health applications. Conagen’s dihydro resveratrol is made by bioconversion from p-coumaric acid (pCA), a natural preservative Conagen produced by precision fermentation. The same proprietary bioconversion technology used to make dihydro resveratrol can be used to make resveratrol and other polyphenol class molecules. Both compounds are natural metabolites of plants, such as berries and grapes, and are commonly found in red wine. Because resveratrol and dihydro resveratrol exist in only very small quantities in plants, cultivation, extraction, and purification are very inefficient, using more land, water, and energy. Instead, Conagen starts with pCA made using fermentation of microorganisms. Bioconversion of pCA allows Conagen to use a much smaller footprint to make dihydro resveratrol and related compounds. “The development of dihydro resveratrol demonstrates Conagen’s

Hisense Elevates Home Entertainment for Africans with Upgraded High-Performance ULED Displays

CAPE TOWN, South Africa, May 31, 2022 /PRNewswire/ — Hisense, provider of high-performance TV and home appliances, has announced it will bring four high-performance ULED display products to the African market: the U80H ULED 8K Mini LED TV, U8H Mini-LED ULED 4K TV, U7H 120Hz Quantum ULED 4K TV, and U6H Quantum ULED 4K TV. The products will launch in the African market in June 2022. Hisense’s latest 2022 ULED series delivers marked improvements on its predecessors, with enhanced visual and audio quality for extraordinary vivid, bright and immersive images. With four Mini-LED TV models across two series, consumers are spoiled for choice when selecting the perfect display for their home. All four new displays support Quantum Dot Colour so users can step into a new world of colours with over 1 billion shades available. Dolby Vision IQ and HDR 10+ Adaptive are supported in U7H models and above to

Billups Accelerates European Expansion and Taps Top Talent to Tackle Growing OOH Demand

AMSTERDAM, May 31, 2022 /PRNewswire/ — Billups, the largest privately held out-of-home (OOH) technology and managed services company in the U.S., today announced key new hires to strengthen its expansion across Europe. The company is experiencing unprecedented growth in both the U.S. and EMEA, with two new ad tech acquisitions earlier this year, new client wins and patent approvals in the location intelligence space. “2021 was the best Billups year since Heather [Billups] and I co-founded the company almost 20 years ago,” said Benjamin Billups, Co-founder of Billups. “Today, we are moving at an accelerated pace where acquisitions and expansion are important to growth, but it is truly the talent we bring on who will transform tomorrow’s OOH industry.” After Billups’ European launch last fall, led by Andrew Brunton, Managing Director, EMEA, the company has partnered with some of the world’s most influential brands to advance OOH as a pillar to

Cleveland Clinic Abu Dhabi completes surgical first in UAE

ABU DHABI, Physicians at Cleveland Clinic Abu Dhabi have successfully performed a valve-in-valve transcatheter mitral valve replacement (VIV-TMVR) in a clinical first for the United Arab Emirates. The 77-year-old patient, Sfeir Iskandar, who had a history of prior coronary artery bypass graft surgery (CABG) and mitral valve replacement, was referred to the specialists at Cleveland Clinic Abu Dhabi with recurrent heart failure. He was found to have severe mitral valve regurgitation (valve leaking) and failure of his mitral valve. His complex case was further exacerbated by the fact that he had multiple medical problems, having previously suffered a stroke, and been diagnosed with kidney disease, while also being significantly frail. Dr. Ahmad Edris, Interventional Cardiologist at Cleveland Clinic Abu Dhabi’s Heart, Vascular and Thoracic Institute, explained, “We are at a stage in our structural heart programme that we can treat very complex valvular heart disease using minimally invasive techniques with